Organization
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
18 abstracts
Abstract
Prognosis of locoregional recurrence after early breast cancer with immediate breast reconstruction.Org: Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, Department of Breast Surgery, Japanese Red Cross Medical Center/Department of Breast Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan, Department of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kanagawa, Japan, Yokohama City University Medical Center, Yokohama, Japan,
Abstract
Neoadjuvant therapy using PD-1 inhibitor plus chemotherapy with different intervals between chemotherapy cycles for locally advanced gastric or gastroesophageal junction cancer: A randomized phase 2 study.Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Department of Immunology and Oncology, Clínica Universidad de Navarra, Henan Cancer Hosptal, Surgical Oncology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University,
Abstract
Prevalence of somatic PIK3CA mutations in hormone receptor-positive metastatic breast cancer: The Indian experience.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Dr. BRA-IRCH, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
Bi-institutional spline curve analysis of lymph node mapping in gallbladder cancer operated over 12 years: Impact of location and number of lymph nodal stations.Org: Tata Memorial Hospital (HBNI), Tata Memorial Centre, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Tata Memorial Center (HBNI),
Abstract
Profile of breast cancer in patients with Li-Fraumeni syndrome: An institutional experience.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Dr. BRA-IRCH, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Real-world treatment practices in patients with muscle invasive bladder cancer (MIBC) treated in Alberta, Canada.Org: University of Calgary, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Princess Margaret Cancer Center, University Health Network, University of British Columbia,
Abstract
Quality of life outcomes in patients with resectable dedifferentiated liposarcoma treated with neoadjuvant immunotherapy.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
DIRECT2: A randomized phase III trial with a fasting mimicking diet program to improve chemotherapy in patients with hormone receptor positive, HER2-negative breast cancer—A Dutch Breast Cancer Research Group study (BOOG).Org: Leiden University Medical Center, Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou, China,
Abstract
An open-label window of opportunity trial to evaluate the activity of durvalumab and tremelimumab with platinum-based chemotherapy (gemcitabine and cisplatin) in intrahepatic cholangiocarcinoma.Org: Emory University School of Medicine, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Birmingham, AL, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.Org: Juntendo University School of Medicine, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Hiroshima University, National Cancer Center Hospital Japan East, Kashiwa, Japan, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.Org: Division of Surgical Oncology, Department of Surgery, The Ohio State University, Netherlands Cancer Institute, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, The Netherlands Cancer Institute,
Abstract
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.Org: Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, Core Laboratory, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, Department of Breast and Endocrine Surgery, Akita University Hospital, Akita, Japan,
Abstract
The prognostic value of degree of pre- and post-treatment anemia in patients with advanced gastroesophageal cancers.Org: University of Toronto, Princess Margaret Cancer Centre, University Health Network, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Department of Surgery, Brigham and Women's Hospital, Boston, MA,
Abstract
Survival outcomes of BRCA1/BRCA2 mutated breast cancers: Study from a tertiary care cancer centre in India.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, BRA-IRCH, National Cancer Institute, Vilnius, Lithuania, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
Results of digital patient-reported outcomes measures (PROMs) data collection for patients with localized prostate cancer at diagnosis.Org: Institut Paoli-Calmettes, Marseille, France, Paoli-Calmettes Institute, Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
Capturing age-related changes in the tumor microenvironment of luminal breast cancer using the multiplex immunohistochemistry technique, MILAN.Org: Laboratory of Experimental Oncology (LEO), Laboratory for Translational Cell and Tissue Research, Multidisciplinary Breast Center, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, University Hospitals Leuven, Leuven, Belgium,
Abstract
Retrospective study of combined pelvic organ resection in the treatment of primary and recurrent pelvic malignant tumors.Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
Effect of reducing the number of neoadjuvant chemoimmunotherapy cycles on clinical efficacy in locally advanced PD-L1 positive gastric cancer: A single center phase 2 study.Org: Department of Immunology and Oncology, Clínica Universidad de Navarra, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Department of Gastrointestinal Surgery, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong, China, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,